Journal of Surgical Research
Volume 141, Issue 2 , Pages 153-161 , August 2007

Reduction of Post-Surgical Adhesion Formation with Tranilast

  • Kevin Cooper, Ph.D.

      Affiliations

    • Center for Biomaterials & Advanced Technologies, Medical Devices Group, A division of Ethicon, A Johnson & Johnson Company, Somerville, New Jersey
    • ,
  • Janel Young, B.S.

      Affiliations

    • Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, New Jersey
    • ,
  • Scott Wadsworth, Ph.D.

      Affiliations

    • Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, New Jersey
    • ,
  • Helen Cui

      Affiliations

    • Center for Biomaterials & Advanced Technologies, Medical Devices Group, A division of Ethicon, A Johnson & Johnson Company, Somerville, New Jersey
    • ,
  • Gere S. diZerega, M.D.

      Affiliations

    • University of Southern California, Keck School of Medicine, Department of Obstetrics & Gynecology, Livingston Reproductive Biology Laboratories, Los Angeles, California
    • Corresponding Author InformationTo whom correspondence and reprint requests should be addressed at Department of Obstetrics & Gynecology, University of Southern California, Keck School of Medicine, Livingston Reproductive Biology Laboratories, 1321 N. Mission Road, Los Angeles, CA 90033.
    • ,
  • Kathleen E. Rodgers, Ph.D.

      Affiliations

    • University of Southern California, Keck School of Medicine, Department of Obstetrics & Gynecology, Livingston Reproductive Biology Laboratories, Los Angeles, California

Received 30 March 2006

References 

  1. Interceed (TC7) Adhesion Barrier Group. Prevention of post surgical adhesions by intercede (TC7), an absorbable adhesion barrier: A prospective randomized multicenter clinical study. Fertil Steril. 1989;51:933
  2. Diamond MP Seprafilm Adhesion Study Group. Reduction of adhesions after uterine myomectomy by Seprafilm (HAL-F): A blinded, prospective, randomized, multicenter clinical study. Fertil Steril. 1996;66:904
  3. Surgical Membrane Study Group. Prophylaxis of pelvic sidewall adhesion formation with Gore-Tex surgical membrane: A multicenter clinical investigation. Fertil Steril. 1992;57:921
  4. Johns DB, Keyport GM, Hoehler F, et al. Intergel adhesions prevention study group: Reduction of PDStsurgical adhesions with Intergel adhesion prevention solution (A multicenter study of safety and efficacy after conservative gynecologic surgery). Fertil Steril. 2001;76:595
  5. Lundorff P, Donnez J, Korell M, et al. Clinical evaluation of a viscoelastic gel for reduction of adhesions following gynaecological surgery by laparoscopy in Europe. Fertil Steril. 2005;20:514
  6. diZerega GS, Verco SJS, Young P, et al. A randomized, controlled pilot study of the safety and efficacy of 4% icodextrin solution in the reduction of adhesions following laparoscopic gynaecological surgery. Hum Reprod. 2002;17:1031
  7. Johns DA, Ferland R, Dunn RI. Initial feasibility study of a sprayable hydrogel adhesion barrier system in patients undergoing laparoscopic ovarian surgery. J Am Assoc Gynecol Laparosc. 2003;10:339
  8. Lundorff P, Donnez J, Korell M, et al. Clinical evaluation of a viscoelastic gel for reduction of adhesions following gynaecological surgery by laparoscopy in Europe. Fertil Steril. 2005;20:514
  9. Young P, Johns A, Templeman C, et al. Reduction of PDStoperative adhesions following laparoscopic gynecological surgery with Oxiplex/AP Gel: A pilot study. Fertil Steril. 2005;84:1450
  10. Mettler L, Audebert A, Lehmann W, et al. Prospective clinical trial of SprayGel as a barrier to adhesion formation: An interim analysis. J Am Assoc Gynecol Laparosc. 2003;10:339
  11. Tulandi T. Introduction-prevention of adhesion formation: The journey continues. Hum Reprod Update. 2001;7:545
  12. Trew G. Consensus in adhesion reduction management. Obstet Gynecol. 2004;6:1
  13. Al-Musawi D, Thompson JN. Adhesion prevention: State of the art. Gynecol Endoscopy. 2001;10:123
  14. Canis M, Botchorishvili R, Tambiurro SM. Adhesion prevention in the surgical treatment of pelvic endometriosis. Gynecol Endoscopy. 2001;10:99
  15. Rodgers KE, diZerega GS. Developing Pharmacologic agents for adhesions prevention. In:  diZerega GS editors. Peritoneal surgery. New York: Springer-Verlag; 2000;p. 441
  16. Jackson JK, Skinner KC, Burgess L, et al. Paclitaxed-loaded crosslinked hyaluronic acid films fro the prevention of PDStsurgical adhesions. Pharm Res. 2002;19:411
  17. Ozugn H, Cevikel MH, Kozaci LD, et al. Lexipafant inhibits PDStsurgical adhesion formation. J Surg Res. 2002;103:141
  18. Duran B, Ak D, Cetin A, et al. Reduction of PDStoperative adhesions by N, O-Carboxymethylchitosan and spermine NONOate in rats. Esp Anim. 2003;52:267
  19. Reed KL, Brent-Fruin A, Gower AC, et al. A neurokinin 1 receptor antagonist decreases PDStoperative peritoneal adhesion formation and increases peritoneal fibrinolytic activity. PNAS. 2004;101:9115
  20. Holmes DR, Savage M, LaBlanche JM, et al. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation. 2002;106:1243
  21. Garot P, Lefevre T, Savage M, et al. Nine-month outcome of patients treated by percutaneous coronary interventions for bifurcation lesions in the recent era: A report from the Prevention of Restenosis with Tranilast and its Outcomes (Presto) trial. J Am Coll Cardiol. 2005;46:606
  22. Topley N. Cytokine responses to peritoneal inflammation. In:  diZerega GS editors. Peritoneal surgery. New York: Springer-Verlag; 2000;p. 75
  23. Yasukawa T, Kimura H, Dong J, et al. Effect of tranilast on proliferation, collagen gel contraction, and transforming growth factor beta secretion of retinal pigment epithelial cells and fibroblasts. Ophthalmic Res. 2002;34:206
  24. Miyazawa K, Kikuchi S, Fukuyama J, et al. Inhibition of PDGF- and TGF-beta 1-induced collagen synthesis, migration and proliferation by tranilast in vascular smooth muscle cells from spontaneously hypertensive rats. Atherosclerosis. 1995;118:213
  25. Ward MR, Agrotis A, Kanellakis P, et al. Tranilast prevents activation of transforming growth factor-β system, leukocyte accumulation, and neointimal growth in porcine coronary arteries after stenting. Arterioscler Thromb Vasc Biol. 2002;22:940
  26. Ward MR, Sasahara T, Agrotis A, et al. Inhibitory effects of tranilast on expression of transforming growth factor-beta isoforms and receptors in injured arteries. Atherosclerosis. 1998;137:267
  27. Adachi S, Maruyama T, Kondo T, et al. The prevention of PDStoperative intraperitoneal adhesions by tranilast: N-(3′,4′-dimethoxycinnamoyl) anthranilic acid. Surg Today. 1999;29:51
  28. Koda A, Kurashina Y, Nakazawa M. The inhibition mechanism of histamine release by N-(3,4-dimethoxycinnamoyl) anthranilic acid. Int Arch Allergy Appl Immunol. 1985;77:244
  29. Liebman SM, Langer JC, Marshall JS, et al. Role of mast cells in peritoneal adhesion formation. Am J Surg. 1993;165:127
  30. Xu X, Rivkind A, Pappo O, et al. Role of mast cells and myofibroblasts in human peritoneal adhesion formation. Ann Surg. 2003;236:593
  31. Fukuyama J, Miyazawa K, Hamano S, et al. Inhibitory effects of tranilast on proliferation, migration, and collagen synthesis of human vascular smooth muscle cells. Can J Physiol Pharmacol. 1996;74:80
  32. Shime H, Kariya M, Orii A, et al. Tranilast inhibits the proliferation of uterine leiomyoma cells in vitro through G1 arrest associated with the induction of p21waf1 and p53. J Clin Endocrinol Metabol. 2002;87:5610
  33. Inoue H, Ohshima H, Kono H, et al. Suppressive effects of tranilast on the expression of inducible cyclooxygenase (COX2) in interleukin-1β-stimulated fibroblasts. Biochem Pharmacol. 1997;53:1941
  34. Suzawa H, Kikuchi S, Ichikawa K, et al. Inhibitory action of tranilast, an anti-allergic drug, on the release of cytokines and PGE2 from human monocytes-macrophages. Jpn J Pharmacol. 1992;60:85;a
  35. Chikaraishi A, Hirahashi J, Takase O, et al. Tranilast inhibits interleukin-1β-induced monocyte chemoattractant protein-1 expression in rat mesangial cells. Eur J Pharmacol. 2001;427:151
  36. Suzawa H, Kikuchi S, Arai N, et al. The mechanism involved in the ingibitory action of tranilast on collagen biosynthesis of keloid fibroblasts. Jpn J Pharmacol. 1992;60:91
  37. diZerega GS. Peritoneum, peritoneal healing, and adhesion formation. In:  diZerega GS editors. Peritoneal surgery. New York: Springer-Verlag; 2000;p. 3
  38. Yamada H, Tajima S, Nishikawa T, et al. Tranilast, a selective inhibitor of collagen synthesis in human skin fibroblasts. J Biochem. 1994;116:892
  39. Akahori H, Ota T, Torita M, et al. Tranilast prevents the progression of experimental diabetic nephropathy through suppression of enhanced Extracellular matrix gene expression. Pharmacol Exp Ther. 2005;27:147
  40. Martin J, Kelly DJ, Mifsud SA, et al. Tranilast attenuates cardiac matrix dePDSition in experimental diabetes: Role of transforming growth factor-beta. Cardiovasc Res. 2005;65:694
  41. Mori H, Tanaka H, Kawada K, et al. Suppressive effects of tranilast on pulmonary fibrosis and activation of alveolar macrophages in mice treated with bleomycin: Role of alveolar macrophages in the fibrosis. Jpn J Pharmacol. 1995;67:279
  42. Isaji M, Aruga N, Naito J, et al. Inhibition by tranilast of collagen accumulation in hypersensitive granulomatous inflammation in vivo and of morphological changes and functions of fibroblasts in vitro. Life Sci. 1994;55:PL287

PII: S0022-4804(06)00263-0

doi: 10.1016/j.jss.2006.05.044

Journal of Surgical Research
Volume 141, Issue 2 , Pages 153-161 , August 2007

Article Tools

* Image Usage & Resolution